RxDoctor Payments Data

Yahaira Moreno Denizard, MD

Gastroenterology · San Juan, PRNPI 1982898490

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.4%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 71.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $2,658 and has fallen 81.8% since, to $483 in 2025.

$8,584in general payments, 2019–2025

Across 117 payments — averaging $73.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Johnson & Johnson$967
  • E.r. Squibb & Sons, L.L.C.$695
  • Janssen Scientific Affairs, LLC$216
  • PBG Puerto Rico LLC$159
  • Olympus Latin America, Inc.$147
  • plus $292 from 6 others

What the payments were for

  • Consulting fees$4,83856%
  • Food & beverage$3,62742%
  • Education$1191%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,584 in reported general payments places this provider in the 85th percentile of 198 gastroenterology providers in Puerto Rico.

See all gastroenterology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$16,105
Medicare patients
34
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sucralfate65$12,639
Mesalamine22$12,428
SuprepSodium, Potassium,mag Sulfates98$11,527
SutabSod Sulf/Pot Chloride/Mag Sulf61$9,910
LinzessLinaclotide18$9,760
Mesalamine DrMesalamine18$8,782
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates59$4,597
Tetracycline Hcl14$1,664
Famotidine153$1,420
Pantoprazole Sodium79$751
Omeprazole117$725
Midazolam Hcl164$421
Midazolam HclMidazolam Hcl/Pf119$324
Fentanyl CitrateFentanyl Citrate/Pf86$302
Lidocaine Hcl ViscousLidocaine Hcl49$222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$6,108$9,76018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 198 gastroenterology providers in Puerto Rico.

Other gastroenterology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →